Highlights Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.234 ^SEK	+5.88%		-13.33%	-97.66%

May. 22	Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®?	CI
May. 16	Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®?	May. 22	CI
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	May. 10	MT
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Xbrane Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Xbrane Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
Xbrane Biopharma AB Focuses on Development Portfolio and Introduces A Cost-Savings Scheme	Nov. 23	CI
Xbrane Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Xbrane Biopharma AB Announces U.S. FDA Filing Acceptance for A LucentisÂ®? (Rranibizumab) Biosimilar Candidate	23-06-21	CI
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Xbrane Biopharma, Stada Jointly Launch Lucentis Biosimilar in Germany	23-05-26	MT
STADA Arzneimittel Aktiengesellschaft and Xbrane Biopharma AB Launch Ximluci® as Ranibizumab Biosimilar in Germany	23-05-26	CI
Xbrane Biopharma AB Submits BLA for Runibizumab Biosimilar Candidate to FDA	23-04-24	CI
STADA Arzneimittel Aktiengesellschafta and Xbrane Biopharma AB Launch Ranibizumab to Support Patient Access in Europe	23-04-03	CI
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Xbrane Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Xbrane Provides an Update on Ranibizumab Biosimilar Candidate FDA Filing	22-12-15	CI
STADA Arzneimittel AG and Xbrane Biopharma AB Secures EU Approval for Ximluci (Ranibizumab) Biosimilar Referencing Lucentis	22-11-11	CI
Xbrane Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-28	CI
STADA Arzneimittel AG and Xbrane Biopharma AB Announce European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion for Ximluci	22-09-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

Highlights

Filters